|1.||Capper-Spudich, Elizabeth A: 1 article (06/2008)|
|2.||Marquis, Robert W: 1 article (06/2008)|
|3.||Locastro, Stephen M: 1 article (06/2008)|
|4.||Long, Edward: 1 article (06/2008)|
|5.||Podolin, Patricia L: 1 article (06/2008)|
|6.||Fox, Josephine H: 1 article (06/2008)|
|7.||Carpenter, Donald C: 1 article (06/2008)|
|8.||McQueney, Michael S: 1 article (06/2008)|
|9.||Dong, Xiaoyang: 1 article (06/2008)|
|10.||Peterson, John J: 1 article (06/2008)|
|1.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
05/01/2002 - "In this study, a potent, nonpeptide inhibitor of rat cathepsin K (K(i) = 4.7 nmol/L), 5-(2-morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-methyl-1-(3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-ethenoyl]-azepan-4-ylcarbanoyl)-butyl)-amide (SB 331750), is described, which is efficacious in rat models of bone resorption. "
05/01/2002 - "In an in situ enzyme assay, SB 331750 inhibited osteoclast-associated cathepsin activity in tissue sections containing human osteoclasts (IC(50) approximately 60 nmol/L) and this translated into potent inhibition of human osteoclast-mediated bone resorption in vitro (IC(50) approximately 30 nmol/L). "
05/01/2002 - "Together, these data indicate that the cathepsin K inhibitor, SB 331750, prevented bone resorption in vivo and this inhibition resulted in prevention of ovariectomy-induced loss in trabecular structure."
05/01/2002 - "In vitro, SB 331750 partially, but dose-dependently, prevented the parathyroid hormone-induced hypercalcemia in an acute rat model of bone resorption. "
|4.||Hypercalcemia (Milk Alkali Syndrome)
|1.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|4.||Parathyroid Hormone (Parathormone)